Director, Clinical Strategy at HeartFlow

San Francisco, California, United States

HeartFlow Logo
Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Medical Technology, Healthcare, Artificial IntelligenceIndustries

Requirements

Candidates must possess over 10 years of experience in clinical research and strategy, with at least 8 years specifically in cardiovascular medicine within the pharmaceutical or medical device industry. A deep understanding of cardiovascular medicine, health technologies, clinical trial strategy, and digital health is essential. The role requires exceptional organizational and presentation skills, excellent attention to detail, and comfort in a fast-paced startup environment. A strategic mindset, patient-centric values, high ethical and compliance standards, and the ability to work independently with minimal supervision are also necessary. The position requires the ability to travel up to 25% and cultural intelligence for international settings.

Responsibilities

The Director, Clinical Strategy will develop clinical evidence strategies for current and future products, ensuring alignment with product development and go-to-market plans. They will collaborate with Clinical Leadership to design clinical trials and real-world evidence studies that validate the safety, efficacy, and impact of Heartflow's AI-enabled products. This role involves supporting key scientific publication activities, representing the company to expert groups, medical societies, patient representatives, and regulatory bodies, and presenting at national and international scientific meetings. Responsibilities also include leading compliant scientific and medical exchange, establishing strong relationships with external advisors, and partnering with Medical Affairs and Clinical Leadership to plan and conduct Advisory Boards related to clinical trial strategy. The Director will monitor trends in cardiology, clinical AI, digital health, regulatory, and reimbursement landscapes to inform clinical strategy and collaborate with clinical advisors, key opinion leaders, investigators, and academic institutions.

Skills

Clinical Strategy
Clinical Evidence Generation
AI in Healthcare
Digital Health
Cardiology
Regulatory Affairs
Market Access
Medical Affairs
Product Marketing
Key Opinion Leader (KOL) Engagement
Academic Institution Collaboration

HeartFlow

Non-invasive cardiac testing for heart disease

About HeartFlow

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main clients are healthcare professionals seeking safer diagnostic methods. The company offers several analyses, including FFRCT Analysis and Plaque Analysis, all of which have received FDA clearance and are available in multiple countries, including the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a comprehensive suite of analyses that enhance treatment planning. The goal of HeartFlow is to improve cardiovascular care by making it safer and more efficient for both patients and healthcare providers.

Redwood City, CaliforniaHeadquarters
2010Year Founded
$858.5MTotal Funding
SERIES_FCompany Stage
HealthcareIndustries
501-1,000Employees

Benefits

Remote Work Options
Stock Options
401(k) Company Match

Risks

Emerging AI-driven competitors could threaten HeartFlow's market share.
Algorithmic bias in AI models could lead to inaccurate diagnoses.
Integration into healthcare systems may face resistance due to complexity and cost.

Differentiation

HeartFlow offers the only combined anatomy, physiology, and plaque analysis for heart disease.
HeartFlow's non-invasive FFRCT Analysis is FDA-cleared and widely available globally.
HeartFlow's AI-driven technology provides personalized 3D heart models for precise diagnostics.

Upsides

HeartFlow closed a $215 million Series F funding round in April 2023.
The global non-invasive cardiac imaging market is projected to grow significantly.
HeartFlow's technology aligns with the trend towards value-based care in healthcare.

Land your dream remote job 3x faster with AI